Life Sciences & Medicine Active Updated Nov 22, 2026
Drugs finally grip the RAS cancer switch
Where it stands as of Nov 22, 2026
RAS-targeting drugs are now shrinking pancreatic and lung tumors in early trials. In 61 untreated metastatic pancreatic cancer patients, daraxonrasib plus chemotherapy shrank or cleared tumors in 60.7%, and the median time before tumors returned was 12.8 months, against five to six months typical with chemotherapy alone. The ERAS-0015 results come from a phase I trial with about four months of follow-up, and whether any of this extends survival is not yet known.
The story so far
-
Nov 22, 2026 Latest
At the EORTC-NCI-AACR symposium in Barcelona, the AURORAS-1 phase I trial of the pan-RAS molecular glue ERAS-0015 reported tumors shrinking considerably in 44% of 83 pancreatic cancer patients and 60% of 37 lung cancer patients who had already tried other treatments. A second trial gave daraxonrasib plus chemotherapy to 61 untreated metastatic pancreatic cancer patients, and tumors shrank or disappeared in 60.7%, with a median 12.8 months before progression.
This story moves with the morning letter.
When this question gets a new answer, the page above changes the same morning. Each morning's letter brings the day's progress in science, medicine and beyond. Free, every day.
Free for good. One click to leave.